citalopram has been researched along with n-(1-adamantyl)-1-(5-fluoropentyl)-1h-indazole-3-carboxamide in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abouchedid, R; Archer, JR; Dargan, PI; Dines, A; Ho, JH; Hudson, S; Wood, DM | 1 |
1 other study(ies) available for citalopram and n-(1-adamantyl)-1-(5-fluoropentyl)-1h-indazole-3-carboxamide
Article | Year |
---|---|
Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation.
Topics: Adamantane; Administration, Intravenous; Anti-Anxiety Agents; Cannabinoid Receptor Agonists; Citalopram; Female; Fluoxetine; Hallucinations; Hallucinogens; Humans; Indazoles; Indoles; Lysergic Acid Diethylamide; Midazolam; Psychomotor Agitation; Quinolines; Seizures; Tachycardia; Time Factors; Young Adult | 2016 |